节点文献

基于数据挖掘探讨国医大师邹燕勤辨治肾癌术后的用药规律

The medication rule of treating renal carcinoma after surgery from TCM master ZOU Yanqin based on data mining

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【摘要】 目的:本研究通过搜集邹燕勤教授诊治肾癌术后的有效医案挖掘其临床用药规律。方法:通过整理门诊系统的102份医案,运用Microsoft Excel、SPSS Modeler软件进行用药频数、因子分析和关联规则分析,挖掘医案中的症状、治法、药物频次、药物组合和核心处方。结果:临床主要症状排名较靠前的为腰酸或痛、疲劳、尿频;12类治法中居前3位者分别为补肾法、和络法、健脾法;使用频率占总医案40%以上的中药共25味,排名居前3位的是黄芪、续断和白花蛇舌草;基于关联规则,得到药物组合45个,频次最高者为“黄芪-茯苓”;置信度设置为0.8,对使用频次≥90的药物组合进行关联规则分析,其中置信度最高者为“槲寄生-续断”(置信度为1);基于聚类分析共提取出3个有效核心处方。结论:本研究一定程度上挖掘出了邹教授辨治肾癌术后的用药特点和核心理念,但仍有局限。

【Abstract】 Objective: The medication rules of Professor ZOU Yanqin in treating renal carcinoma after surgery were explored by analyzing the effective medical records. Methods: A total of 102 effective medical records in the outpatient system were collected to establish a database. Microsoft Excel and SPSS Modeler software were used to analyze the medication frequency, factor and association rules. The symptoms, treatment methods, medication frequencies, medicine combination and core prescriptions in the medical records were mined. Results: The main clinical symptoms ranked the top were soreness of waist, fatigue, frequent urination. Among the 12 types of treatment methods, the top 3 were tonifying the kidney, dredging the meridian and collateral, and invigorating the spleen methods.There were 25 TCM medicines used more than 40% of the total medical records, and the top 3 were Huangqi(radix astragali), Xuduan(dipsacales), and Baihua Sheshe Cao(hedyotis diffusa). Based on association rules, a total of 45 medicine combinations were obtained, and Huangqi-Fuling(poria) has the highest frequency. The confidence level was set to 0.8, and the association rule analysis was conducted on the medicine combinations with a medication frequency greater than 90. Among them, Hujisheng(mistletoe)-Xuduan had the highest confidence level(the confidence level was 1). Furthermore, there were 3 effective core prescriptions which were extracted based on cluster analysis. Conclusion: To a certain extent, this study excavates the characteristics and core concepts of Professor ZOU’s medication on renal carcinoma after surgery, but there were still some limitations.

【基金】 国家自然科学基金(NO:81873270);江苏省卫生和计划生育委员会(NO:BJ15021);江苏省中医药科技发展计划项目(NO.YB201913)
  • 【文献出处】 中医临床研究 ,Clinical Journal of Chinese Medicine , 编辑部邮箱 ,2022年23期
  • 【分类号】R249;R273
  • 【下载频次】97
节点文献中: